Ripertamab for Generalized Myasthenia Gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new medicine, ripertamab, for people with generalized myasthenia gravis (gMG). It aims to see if targeting certain immune cells can help reduce symptoms like muscle weakness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have generalized myasthenia gravis (gMG), not just eye muscle symptoms.
- You have specific antibodies (AChR, MuSK, or LRP4) in your blood.
- Your MG-ADL symptom score is 6 or higher, with most symptoms not related to eyes.
- You haven't used certain immune-suppressing drugs, rituximab, or similar treatments recently.
- You haven't had a thymectomy (thymus gland removal) in the last year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called empasiprubart for people with generalized myasthenia gravis (gMG) who have a certain antibody (AChR-Ab). It is given as a monthly IV infusion (into a vein) and aims to improve muscle weakness and daily functioning.
This Phase 3 trial tests rituximab (an immune system medicine) to see if it improves myasthenia gravis (MG) symptoms and function. It’s for adults with confirmed MG and moderate-to-severe impact on daily activities despite current care.
This trial tests a new medication (remibrutinib) versus a placebo to see if it helps adults with generalized myasthenia gravis. You may qualify if your symptoms affect multiple parts of your body and you haven't had certain recent treatments.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial tests a new drug called ripeltumab in people with neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation of the optic nerve and spinal cord. It aims to reduce relapses by targeting the immune system.
This trial tests a new medication called Telitacicept for people with generalized myasthenia gravis (gMG). The goal is to see if it can reduce muscle weakness and improve daily function. You may be able to join if you have moderate to severe symptoms and have not had recent thymoma or other serious health issues.
Hear when a new Myasthenia Gravis (MG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.